Type I Gaucher disease intravenous enzyme replacement therapy: imiglucerase (Cerezyme), velaglucerase (Vpriv), and taliglucerase (Elelyso) - Minnesota Health Care Programs

HealthPartners · PayerPolicy · HEALTHPARTNERS-CC-ENTRY-187835

Source checked May 14, 2026 · Open the payer’s source

Status: Retired

Summary of the payer’s published policy. Not a coverage determination — confirm with HealthPartners before submitting.

This version is retired

HealthPartners has replaced or withdrawn this version, and Backwork could not match it to a current one. The payer’s current policies are listed on its page.

HealthPartners policies Payer’s source